442 related articles for article (PubMed ID: 28377530)
21. Reverse genetic generation of recombinant Zaire Ebola viruses containing disrupted IRF-3 inhibitory domains results in attenuated virus growth in vitro and higher levels of IRF-3 activation without inhibiting viral transcription or replication.
Hartman AL; Dover JE; Towner JS; Nichol ST
J Virol; 2006 Jul; 80(13):6430-40. PubMed ID: 16775331
[TBL] [Abstract][Full Text] [Related]
22. A Novel Agonist of the TRIF Pathway Induces a Cellular State Refractory to Replication of Zika, Chikungunya, and Dengue Viruses.
Pryke KM; Abraham J; Sali TM; Gall BJ; Archer I; Liu A; Bambina S; Baird J; Gough M; Chakhtoura M; Haddad EK; Kirby IT; Nilsen A; Streblow DN; Hirsch AJ; Smith JL; DeFilippis VR
mBio; 2017 May; 8(3):. PubMed ID: 28465426
[TBL] [Abstract][Full Text] [Related]
23. Ebolaviruses Associated with Differential Pathogenicity Induce Distinct Host Responses in Human Macrophages.
Olejnik J; Forero A; Deflubé LR; Hume AJ; Manhart WA; Nishida A; Marzi A; Katze MG; Ebihara H; Rasmussen AL; Mühlberger E
J Virol; 2017 Jun; 91(11):. PubMed ID: 28331091
[TBL] [Abstract][Full Text] [Related]
24. Daunorubicin, a topoisomerase II poison, suppresses viral production of hepatitis B virus by inducing cGAS-dependent innate immune response.
Imai H; Dansako H; Ueda Y; Satoh S; Kato N
Biochem Biophys Res Commun; 2018 Oct; 504(4):672-678. PubMed ID: 30209005
[TBL] [Abstract][Full Text] [Related]
25. Dengue Virus NS Proteins Inhibit RIG-I/MAVS Signaling by Blocking TBK1/IRF3 Phosphorylation: Dengue Virus Serotype 1 NS4A Is a Unique Interferon-Regulating Virulence Determinant.
Dalrymple NA; Cimica V; Mackow ER
mBio; 2015 May; 6(3):e00553-15. PubMed ID: 25968648
[TBL] [Abstract][Full Text] [Related]
26. Ebola virus VP35 perturbs type I interferon signaling to facilitate viral replication.
Cao Z; Liu C; Peng C; Ran Y; Yao Y; Xiao G; Li E; Chen Z; Chuai X; Chiu S
Virol Sin; 2023 Dec; 38(6):922-930. PubMed ID: 37839549
[TBL] [Abstract][Full Text] [Related]
27. Targeting Innate Immunity for Antiviral Therapy through Small Molecule Agonists of the RLR Pathway.
Pattabhi S; Wilkins CR; Dong R; Knoll ML; Posakony J; Kaiser S; Mire CE; Wang ML; Ireton RC; Geisbert TW; Bedard KM; Iadonato SP; Loo YM; Gale M
J Virol; 2015 Dec; 90(5):2372-87. PubMed ID: 26676770
[TBL] [Abstract][Full Text] [Related]
28. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3.
Basler CF; Mikulasova A; Martinez-Sobrido L; Paragas J; Mühlberger E; Bray M; Klenk HD; Palese P; García-Sastre A
J Virol; 2003 Jul; 77(14):7945-56. PubMed ID: 12829834
[TBL] [Abstract][Full Text] [Related]
29. Signaling through RIG-I and type I interferon receptor: Immune activation by Newcastle disease virus in man versus immune evasion by Ebola virus (Review).
Schirrmacher V
Int J Mol Med; 2015 Jul; 36(1):3-10. PubMed ID: 25998621
[TBL] [Abstract][Full Text] [Related]
30. Ebola virus sequesters IRF3 in viral inclusion bodies to evade host antiviral immunity.
Zhu L; Jin J; Wang T; Hu Y; Liu H; Gao T; Dong Q; Jin Y; Li P; Liu Z; Huang Y; Liu X; Cao C
Elife; 2024 Jan; 12():. PubMed ID: 38285487
[TBL] [Abstract][Full Text] [Related]
31. STING-dependent translation inhibition restricts RNA virus replication.
Franz KM; Neidermyer WJ; Tan YJ; Whelan SPJ; Kagan JC
Proc Natl Acad Sci U S A; 2018 Feb; 115(9):E2058-E2067. PubMed ID: 29440426
[TBL] [Abstract][Full Text] [Related]
32. A Luciferase Reporter Gene Assay to Measure Ebola Virus Viral Protein 35-Associated Inhibition of Double-Stranded RNA-Stimulated, Retinoic Acid-Inducible Gene 1-Mediated Induction of Interferon β.
Cannas V; Daino GL; Corona A; Esposito F; Tramontano E
J Infect Dis; 2015 Oct; 212 Suppl 2():S277-81. PubMed ID: 25926684
[TBL] [Abstract][Full Text] [Related]
33. A high throughput screen identifies benzoquinoline compounds as inhibitors of Ebola virus replication.
Luthra P; Liang J; Pietzsch CA; Khadka S; Edwards MR; Wei S; De S; Posner B; Bukreyev A; Ready JM; Basler CF
Antiviral Res; 2018 Feb; 150():193-201. PubMed ID: 29294299
[TBL] [Abstract][Full Text] [Related]
34. Identification of Myricetin as an Ebola Virus VP35-Double-Stranded RNA Interaction Inhibitor through a Novel Fluorescence-Based Assay.
Daino GL; Frau A; Sanna C; Rigano D; Distinto S; Madau V; Esposito F; Fanunza E; Bianco G; Taglialatela-Scafati O; Zinzula L; Maccioni E; Corona A; Tramontano E
Biochemistry; 2018 Nov; 57(44):6367-6378. PubMed ID: 30298725
[TBL] [Abstract][Full Text] [Related]
35. Differential Regulation of Interferon Responses by Ebola and Marburg Virus VP35 Proteins.
Edwards MR; Liu G; Mire CE; Sureshchandra S; Luthra P; Yen B; Shabman RS; Leung DW; Messaoudi I; Geisbert TW; Amarasinghe GK; Basler CF
Cell Rep; 2016 Feb; 14(7):1632-1640. PubMed ID: 26876165
[TBL] [Abstract][Full Text] [Related]
36. The Ebola virus VP35 protein binds viral immunostimulatory and host RNAs identified through deep sequencing.
Dilley KA; Voorhies AA; Luthra P; Puri V; Stockwell TB; Lorenzi H; Basler CF; Shabman RS
PLoS One; 2017; 12(6):e0178717. PubMed ID: 28636653
[TBL] [Abstract][Full Text] [Related]
37. VP24-Karyopherin Alpha Binding Affinities Differ between Ebolavirus Species, Influencing Interferon Inhibition and VP24 Stability.
Schwarz TM; Edwards MR; Diederichs A; Alinger JB; Leung DW; Amarasinghe GK; Basler CF
J Virol; 2017 Feb; 91(4):. PubMed ID: 27974555
[TBL] [Abstract][Full Text] [Related]
38. Novel activities by ebolavirus and marburgvirus interferon antagonists revealed using a standardized in vitro reporter system.
Guito JC; Albariño CG; Chakrabarti AK; Towner JS
Virology; 2017 Jan; 501():147-165. PubMed ID: 27930961
[TBL] [Abstract][Full Text] [Related]
39. Interferon-Induced HERC5 Inhibits Ebola Virus Particle Production and Is Antagonized by Ebola Glycoprotein.
Paparisto E; Hunt NR; Labach DS; Coleman MD; Di Gravio EJ; Dodge MJ; Friesen NJ; Côté M; Müller A; Hoenen T; Barr SD
Cells; 2021 Sep; 10(9):. PubMed ID: 34572049
[TBL] [Abstract][Full Text] [Related]
40. Emerging Alphaviruses Are Sensitive to Cellular States Induced by a Novel Small-Molecule Agonist of the STING Pathway.
Gall B; Pryke K; Abraham J; Mizuno N; Botto S; Sali TM; Broeckel R; Haese N; Nilsen A; Placzek A; Morrison T; Heise M; Streblow D; DeFilippis V
J Virol; 2018 Mar; 92(6):. PubMed ID: 29263267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
